If radiation were a drug. Full editorial on my blog. #radonc

Full article covering the radiation caveats:.

EMBARK - important data, but know the details. I covered it in depth back in June of 2023 with AUA 2023 Chicago presentation. The details I covered won't change. Just understand it leans on a drug based answer and probably isn't as clean as the headlines.

Great article describing why you need to see multiple studies (hopefully across multiple sites) to really lean into a finding. And being old school, I still like separate studies rather than meta-analysis that potentially just align with publication bias.

RT @GiuliaMarvaso84: 'Better technology cures more patients with less side effects' quoting @alison_tree at the MR and RT symposium in Zuri….

Very out of the box thinking but, at the same time, makes a lot of sense. Anyone seen this used in the US? Thoughts? Do I need more coffee?

Truth is, we constantly "give" on things like forward planned (in the literature "IMRT") treatments and coerce ourselves into planning their game. QR code for link if interested where I relay a duplicate / nearly identical example.

This is crazy - this is why I wrote the "IMRT is the de facto standard of care for the treatment of definitive disease" back when ASTRO was evaluating their IMRT policy.

Notes and thoughts on the recent update of the multi-institutional randomized prospective head and neck proton trial and some important dates to watch for the upcoming - now accrual completed RadComp Breast trial.

RT @Dr_RaviMadan: Sadly this is 💯 correct @ProtonStorey . We are also repeating the mistakes made a generation ago with Gleason 6 #Prostate….

More and more, seeing PSAs well less than 0.5 and even 0.2 in FIR or early UIR getting a PSMA scan post-treatment leading to biopsies and or systemic treatment - based on PROMISE trial v2 score 1 findings.

American physicians love tests and just doing stuff. We are currently repeating the mistakes of PSA leading to too many downstream un-needed procedures with PSMA scans.

Generally huge fan of Quadshot, but here I they ultimately simplified differences away in the final take home. Trial: .Grade 2+ CTCAE GI toxicity: 10% vs 17% favoring 20 fx, p=0.0011 .Grade 2+ CTCAE GU toxicity: 28% vs 34% favoring 20 fx, p=0.050. This is measurably more toxic.

RT @NiuSanford: After our daughter Ceci died at 15 mo of a paraspinal tumor, we’ve been committed to supporting pediatric cancer research.….

Insufficient capacity?? Like UK can't draw blood on that many men? Wow. Obviously that is just poorly written - I hope. And I disagree, I think the data is quite clear.

Gleason 9, low Prolaris - nearly rec AS. Go through references. ~70 men RT Gleason 9 disease - total referenced. Can't even tell if ANY didn't get ADT. Crazy start to the morning.

RT @KamalThippu: 📣#PACE - PACE C trial early toxixity data out now! . 👉

Direct Link to article:

Latest article: PSA screening: So much room for improvement in recommendations to screen and so many opportunities to improve downstream management to limit over-treatment.

RT @mcuban: "Here’s a wild-but-true factoid: 10 of the 20 largest companies on the new Fortune 500 list derive profit from the 340B program….

RT @MyrsiniIoakeim: Plenary session at #PTCOG63: @SJFrankMD presented extended OS data from the randomized trial of IMPT vs IMRT in H&N can….